M&A / Deals Parabilis follows hefty Regeneron deal with IPO push BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritisNext: Beam one-ups Wave as both show promise of genetic editing for AATD Related Stories M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project pharminent June 9, 2026 M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026 M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
